Clinical Laserthermia Systems

Clinical Laserthermia Systems AB develops and commercializes image-guided laser-based therapy systems for minimally invasive tissue ablation. Its platform is used with MRI, ultrasound, or CT guidance and is organized around medical laser systems, disposable instruments, and related software-enabled treatment control, with operations in Sweden and subsidiaries in the United States, Germany, and Singapore.

— Clinical Laserthermia Systems
%
Neurosurgical laser therapy systems55% Image-guided laser systems used in neurosurgery for minimally invasive ablation.
Non-neurosurgical thermal therapy systems20% Laser-based thermal therapy systems used outside neurosurgery.
Disposable instruments and consumables20% Sterile single-use products used with CLS therapy procedures.
Service, support, and commercialization activities5% Clinical, regulatory, and partnership support tied to system deployment.

CLS sells to medical professionals and healthcare institutions that perform minimally invasive ablation procedures...

  • Neurosurgery centersprimary

    Buy ClearPoint Prism systems for brain tumor, epilepsy, and radiation necrosis procedures.

  • Hospital ablation programssecondary

    Use TRANBERG and related systems for minimally invasive thermal therapy.

  • Strategic commercial partnersprimary

    Help place systems and expand market access across regions.

  • Procedure-based end userssecondary

    Purchase disposable instruments and accessories tied to each treatment.

CLS is headquartered in Sweden and has operating subsidiaries in the United States and Germany, plus a 50% joint...

  • •Headquartered in Sweden with global commercialization from Lund
  • •Wholly owned subsidiary in the United States
  • •Wholly owned subsidiary in Germany
  • •50% joint venture in Singapore for Asia-Pacific
  • •Most sales are outside Sweden

CLS is focused on scaling commercial adoption of its Prism and TRANBERG platforms through strategic partnerships,...

01
Scale commercial placementsshort-term

System placements drive recurring disposable demand and procedure growth.

02
Expand regulatory coveragemedium-term

Approvals determine where the systems can be marketed and used clinically.

03
Broaden clinical indicationsmedium-term

More approved uses increase addressable procedures and hospital adoption.

04
Develop next-generation productslong-term

New systems can improve adoption, performance, and competitive differentiation.

CLS depends on clinical adoption, reimbursement, and regulatory approvals, all of which can slow or limit system sales...

high

Reimbursement dependence

CLS procedures rely on national and insurer reimbursement decisions, especially in the U.S.

Scope
Pricing and adoption of treatment methods
Materiality
high
high

Regulatory approval risk

Systems and indications must clear medical-device regulatory pathways before commercialization.

Scope
Market access in new countries and indications
Materiality
high
high

Clinical adoption risk

Hospitals and physicians may adopt slowly if workflows, evidence, or training are insufficient.

Scope
Neurosurgery and ablation procedures
Materiality
high
high

Funding and dilution risk

Growth investment may require external financing before positive cash flow is reached.

Scope
Working capital and expansion plans
Materiality
high
medium

Commercial placement timing

Revenue depends on when systems are installed and procedures ramp up.

Scope
Quarterly revenue volatility
Materiality
medium
Revenue recognition by product type
Revenue timing and quarterly volatility
Capitalized development costs
Operating profit and intangible asset carrying value
Impairment testing of intangibles
Potential non-cash charges
Consolidation of subsidiaries and joint venture
Reported revenue, expenses, and balance sheet
Foreign currency translation
Reported equity and earnings

Gentherm Inc

THRM · Motor Vehicle Parts & Accessories

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

TACTILE SYSTEMS TECHNOLOGY INC

TCMD · Surgical & Medical Instruments & Apparatus

Seres Therapeutics, Inc.

MCRB · Pharmaceutical Preparations

SELECTIS HEALTH, INC.

GBCS · Real Estate Investment Trusts

DiaMedica Therapeutics Inc.

DMAC · Pharmaceutical Preparations

: 11/08/2026